HUE030274T2 - A gyökmegkötõ és antioxidáns alfa-1-mikroglobulin gyógyászati alkalmazása - Google Patents

A gyökmegkötõ és antioxidáns alfa-1-mikroglobulin gyógyászati alkalmazása Download PDF

Info

Publication number
HUE030274T2
HUE030274T2 HUE13172049A HUE13172049A HUE030274T2 HU E030274 T2 HUE030274 T2 HU E030274T2 HU E13172049 A HUE13172049 A HU E13172049A HU E13172049 A HUE13172049 A HU E13172049A HU E030274 T2 HUE030274 T2 HU E030274T2
Authority
HU
Hungary
Prior art keywords
alpha
cells
heme
haemoglobin
blood
Prior art date
Application number
HUE13172049A
Other languages
English (en)
Inventor
Bo Akerstroem
Stefan Hansson
Martin Lennarth Olsson
Magnus Gram
Original Assignee
A1M Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A1M Pharma Ab filed Critical A1M Pharma Ab
Publication of HUE030274T2 publication Critical patent/HUE030274T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Claims (4)

  1. §i$mmLM iOÈNYRONTOK I. ájiM-mpogiiltáiItesszfί járó betegség vagy állapot émemaú mm »«é*4«éi-én»»üt «fâl iá .Időmegkötés kombináoéjévái vég· áéil kelisibéá pegtiÄsilin tbiénii ÉtaNiMsn, aáál ál súesszel mm betegség vagy állapot dialízissel ősszeluggo veseeiágiéien&eg. Z ^^lÉbikrC'giobuun az '>: »génvptiV' ezm» *e a nalnuzásiH oho a u«'· teg ság vágy állápét égytestnemzhen jelenlevő szabad hemoglobinná van §$szi|ig§éshen §, Alfa -1 -mikrogioouün az 1 - vagy 2. igénypont szerinti alkalmazásra, ahol M alfa-1 -mikrogtóbuün a humán alfa-t-mikreglöbuíinnal ( h számú szekvencia) zv gaiább 80%-os i|g«|ággal mpdikfÄ 4. álfárl^blkroglobuiin az előző igénypontok báiwíyiké azábblrái^ mázisía. áho! iá álfá-l -mikrogtobufin humán alfa- 1-misroglobúllb |1; iáiimb Ä· kvenciap I. Alfa* 1 mskroglohuli?? az előző igénypontok bármelyike szenet? alkalmazásra. aboi az aifa-1-mikrogiebuíin a humán mkombinàns alfa A-· mikrogíobolinnét {2. számú azÄtnei# lepiiâbb 80%^ob:áZén^aépa|fébdél-keztk. |. Aifa-t-mikrogtoPuiin az 1-2, és 5. fénypontok bármelyike szerinti ajkak nlizasiá. ahol az aifa-l-mikroglobuiiri humán lekombmans aifa-i -mikröglobüílb pL száma szekvencia), % Alit-ivmikroglőWlfaz sliil Igénypontok hánnaiyike szeheti éigf-: htázásti. ábol az aifa-1-m:lM§fbbúitht: paféntérálsán adagoljuk,
  2. 8. Aífm Yznikroglobulin az előző igénypontok bármelyike szerint! sikál-mbzista, ahol az alfa-t -mikrogiobulint helyileg, például egy testüregbe adagoljuk.
  3. 9, Alfa·· 1 ·mikrogtct>uti?> as slóaó igényoontek bàmieiÿike szerinti alkat tliszasre, adói az alfa*· 1 -mskr aplobulint alfa- nodkrogtobolNit és egy győgyászabiag elfogadható segédanyagot tartalmazd készdmenykéot adagoljuk
  4. 10, Alfa-1 -nékrogiobuNri a 9. igénypont szerinti alkalmazásra, adói a gyógyászatig elfogadható segédanyag oldószerek pH-szabályozó szetek, ozmotikusáé aktiv szerek, koszoiveosek, szoluóimálószerek, emuigeóiószeíék, ázusz|.Ht;ntíáíószerek. felületaktív szerek oedvositoszerek kézül választott
HUE13172049A 2008-07-18 2009-07-17 A gyökmegkötõ és antioxidáns alfa-1-mikroglobulin gyógyászati alkalmazása HUE030274T2 (hu)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13533808P 2008-07-18 2008-07-18
DKPA200801024 2008-07-18
US18938108P 2008-08-18 2008-08-18
DKPA200801116 2008-08-18
US19750608P 2008-10-27 2008-10-27
DKPA200801478 2008-10-27

Publications (1)

Publication Number Publication Date
HUE030274T2 true HUE030274T2 (hu) 2017-05-29

Family

ID=41550762

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE13172049A HUE030274T2 (hu) 2008-07-18 2009-07-17 A gyökmegkötõ és antioxidáns alfa-1-mikroglobulin gyógyászati alkalmazása
HUE09777272A HUE027953T2 (hu) 2008-07-18 2009-07-17 A gyökfogó és antioxidáns alfa-1-mikroglobulin gyógyászati alkalmazása

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE09777272A HUE027953T2 (hu) 2008-07-18 2009-07-17 A gyökfogó és antioxidáns alfa-1-mikroglobulin gyógyászati alkalmazása

Country Status (12)

Country Link
US (1) US10350268B2 (hu)
EP (2) EP2313106B1 (hu)
JP (3) JP5694928B2 (hu)
AU (1) AU2009270435B2 (hu)
CA (1) CA2730531A1 (hu)
DK (2) DK2313106T3 (hu)
ES (2) ES2571956T3 (hu)
HR (2) HRP20160760T1 (hu)
HU (2) HUE030274T2 (hu)
PL (2) PL2313106T3 (hu)
PT (1) PT2638915T (hu)
WO (1) WO2010006809A2 (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932365B2 (en) 2003-11-08 2011-04-26 Pro Thera Biologics, Llc Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
EA022609B1 (ru) 2007-02-12 2016-02-29 А1М Фарма Аб Применение свободного фетального гемоглобина в качестве маркера преэклампсии
ES2673005T3 (es) 2008-05-28 2018-06-19 Prothera Biologics, Inc Preparación y composición de proteínas inter-alfa inhibidoras a partir de sangre
HUE030559T2 (hu) * 2012-09-05 2017-05-29 A1M Pharma Ab Alfa-1-mikroglobulin mitokondriális betegségek kezelésében történõ alkalmazásra
AU2013312215C1 (en) 2012-09-09 2018-09-06 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
EP3102224B1 (en) * 2013-12-20 2019-02-20 NephroGenesis, LLC. Apparatuses for kidney dialysis and lipocalin protein for use in the prevention or treatment of uremia by dialysis
CN108779157B (zh) 2016-03-18 2022-12-30 卫士医疗国际公司 新α-1-微球蛋白衍生蛋白及其应用
WO2018094023A2 (en) * 2016-11-16 2018-05-24 Anand Prasad Cyclic dipeptides and wound healing
CN111511386A (zh) * 2017-11-03 2020-08-07 卫士医疗国际公司 α-1-微球蛋白用于保护骨髓细胞的用途
JP6906807B2 (ja) 2018-08-31 2021-07-21 一般社団法人クラインシュタイン医工学パースペクティブ 透析装置

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166133A (en) * 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
US6103691A (en) * 1994-03-23 2000-08-15 Tschesche; Harald Utilisation of angiogenin and/or α1 -microglobulin and/or complement factor D in order to inhibit the secretion of proteins
US5910482A (en) 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
JP2001348342A (ja) 2001-04-12 2001-12-18 Nippon Zoki Pharmaceut Co Ltd 免疫調整・抗炎症剤
DE10125883A1 (de) * 2001-05-28 2002-12-12 Serumwerk Bernburg Ag Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20070060512A1 (en) * 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
AR045074A1 (es) 2003-07-23 2005-10-12 Applied Research Systems Uso de cd164 soluble en desordenes inflamatorios y autoinmunes
ITMI20032528A1 (it) 2003-12-19 2005-06-20 Francesco Santangelo Uso di cistina o di cisteina per la prevenzione e il
US20060105419A1 (en) 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
JP2007001922A (ja) 2005-06-23 2007-01-11 Asahi Kasei Pharma Kk 透析患者における腎疾患改善剤、又は機能性食品
US20070292421A1 (en) 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
US20080133141A1 (en) 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
EA022609B1 (ru) 2007-02-12 2016-02-29 А1М Фарма Аб Применение свободного фетального гемоглобина в качестве маркера преэклампсии

Also Published As

Publication number Publication date
US10350268B2 (en) 2019-07-16
WO2010006809A2 (en) 2010-01-21
JP6406987B2 (ja) 2018-10-17
JP2012505154A (ja) 2012-03-01
HUE027953T2 (hu) 2017-01-30
ES2571956T3 (es) 2016-05-27
EP2638915B1 (en) 2016-10-19
EP2313106B1 (en) 2016-03-30
JP2016102125A (ja) 2016-06-02
AU2009270435B2 (en) 2014-10-16
JP5694928B2 (ja) 2015-04-01
JP2015071620A (ja) 2015-04-16
WO2010006809A3 (en) 2010-05-27
CA2730531A1 (en) 2010-01-21
PL2313106T3 (pl) 2016-08-31
DK2313106T3 (en) 2016-07-25
PL2638915T3 (pl) 2017-04-28
HRP20160760T1 (hr) 2016-08-12
EP2313106A2 (en) 2011-04-27
HRP20161808T1 (hr) 2017-02-24
PT2638915T (pt) 2017-01-10
US20110190208A1 (en) 2011-08-04
JP6175478B2 (ja) 2017-08-02
EP2638915A1 (en) 2013-09-18
ES2614490T3 (es) 2017-05-31
AU2009270435A1 (en) 2010-01-21
DK2638915T3 (en) 2017-01-30

Similar Documents

Publication Publication Date Title
DK2638915T3 (en) MEDICAL USE OF THE RADICAL BINDER AND ANTIOXIDANT ALFA-1 MICROGLOBULIN
Bulters et al. Haemoglobin scavenging in intracranial bleeding: biology and clinical implications
Olsson et al. Pathological conditions involving extracellular hemoglobin: molecular mechanisms, clinical significance, and novel therapeutic opportunities for α1-microglobulin
Badr Camel whey protein enhances diabetic wound healing in a streptozotocin-induced diabetic mouse model: the critical role of β-Defensin-1,-2 and-3
JP2018203756A (ja) ミトコンドリア関連疾患の治療に使用するためのα−１−ミクログロブリン
KR20090033329A (ko) 가교된 헤모글로빈 혈액 대용품을 사용한 급성 혈액 손실 빈혈의 치료 방법
JP2010538020A (ja) 血管新生および創傷治癒活性がある薬剤
Yang et al. Neurovascular protection by adropin in experimental ischemic stroke through an endothelial nitric oxide synthase-dependent mechanism
US20090291086A1 (en) Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia
AU2014262273B2 (en) Medical use of the radical scavenger and antioxidant alpha-1-microglobulin
Robles et al. Lead exposure effect on angiotensin II renal vasoconstriction
Guner et al. The effect of fluoxetine on ischemia–reperfusion after aortic surgery in a rat model
Sabapathy et al. The Yin and Yang of alarmins in regulation of acute kidney injury
CA2328134A1 (en) The induction of antibiotic proteins and peptides by lait/scd14-protein
McCormick et al. Clinically applicable thermal preconditioning attenuates leukocyte–endothelial interactions
JP2022533365A (ja) 出血性脳卒中後の有害な二次神経学的転帰を処置する際に使用するためのハプトグロビン
Hieu et al. Capacity of extracellular globins to reduce liver fibrosis via scavenging reactive oxygen species and promoting MMP-1 secretion
RU2405558C2 (ru) Лекарственный препарат для лечения гипоксических и токсических митохондриальных нарушений и способ его получения
Suzuki et al. Hemopexins suppress phorbol ester-induced necrosis of polymorphonuclear leucocytes
Spiridonova et al. Etiology and pathogenesis of burn anemia. The role of the blood transfusion in the treatment of patients with burns
US20130165391A1 (en) B2-glycoprotein i peptide inhibitors
Çekmez et al. Comparing beneficial effects of inhaled nitric oxide to L-arginine in necrotizing enterocolitis model in neonatal rats
AbdAl-Salam et al. Adverse effects of moxifloxacin and flunixin meglumine and their combination on pregnant rats
Li et al. Kidney injury in a murine hemorrhagic shock/resuscitation model is alleviated by sulforaphane’s anti-inflammatory and antioxidant action
Dobryszycka Haptoglobin in the new millenium